We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+9.19%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$709M
AUM Growth
-$77.6M
(-9.9%)
Cap. Flow
-$116M
Cap. Flow
% of AUM
-16.41%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
91
Reduced
283
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$8.04M |
| 2 |
Applied Materials
AMAT
|
+$4.9M |
| 3 |
Amphenol
APH
|
+$4.75M |
| 4 |
Arista Networks
ANET
|
+$4.46M |
| 5 |
Alibaba
BABA
|
+$4.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$7.54M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$7.04M |
| 3 |
Adobe
ADBE
|
+$6.93M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$6.31M |
| 5 |
Gilead Sciences
GILD
|
+$4.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
UroGen Pharma
URGN
$2.39B
| $71.2K | 0.01% |
4,244
-1,659
| -28% | -$23.6K |
|
327
Olema Pharmaceuticals
OLMA
$913M
| $71.1K | 0.01% |
6,572
-3,990
| -38% | -$43.3K |
|
328
Phathom Pharmaceuticals
PHAT
$742M
| $70.8K | 0.01% |
6,877
-4,112
| -37% | -$42.4K |
|
329
Zymeworks
ZYME
$1.77B
| $70.7K | 0.01% |
8,306
-5,138
| -38% | -$45.7K |
|
330
Castle Biosciences
CSTL
$960M
| $70.6K | 0.01% |
3,242
-2,055
| -39% | -$45.8K |
|
331
Arbutus Biopharma
ABUS
$907M
| $68.5K | 0.01% |
22,171
-10,062
| -31% | -$30.2K |
|
332
Mineralys Therapeutics
MLYS
$2.38B
| $68.2K | 0.01% |
5,832
-2,099
| -26% | -$26.4K |
|
333
Regenxbio
RGNX
$720M
| $67.7K | 0.01% |
5,786
-2,733
| -32% | -$42.5K |
|
334
Humacyte
HUMA
$179M
| $67.2K | 0.01% |
13,990
-5,893
| -30% | -$30.7K |
|
335
Savara
SVRA
$1.17B
| $65.4K | 0.01% |
16,235
-9,800
| -38% | -$43.6K |
|
|
ITOS
336
DELISTED
iTeos Therapeutics
ITOS
| $65K | 0.01% |
4,378
-2,499
| -36% | -$35.8K |
|
337
Replimune Group
REPL
$1.28B
| $64.9K | 0.01% |
7,214
-4,594
| -39% | -$32K |
|
338
SIGA Technologies
SIGA
$206M
| $63.4K | 0.01% |
8,355
-5,305
| -39% | -$43.2K |
|
|
WBA
339
DELISTED
Walgreens Boots Alliance
WBA
| $62.7K | 0.01% |
5,187
+1,297
| +33% | +$22K |
|
340
Adaptive Biotechnologies
ADPT
$4.02B
| $62.7K | 0.01% |
17,314
-10,582
| -38% | -$33.6K |
|
|
THRD
341
DELISTED
Third Harmonic Bio
THRD
| $62.6K | 0.01% |
4,812
-2,972
| -38% | -$36.8K |
|
342
HUTCHMED
HCM
$2.13B
| $62.4K | 0.01% |
3,645
-2,288
| -39% | -$42.2K |
|
|
YMAB
343
DELISTED
Y-mAbs Therapeutics
YMAB
| $62.3K | 0.01% |
5,156
-3,234
| -39% | -$43.7K |
|
|
CNTA
344
DELISTED
Centessa Pharmaceuticals
CNTA
| $61.5K | 0.01% |
6,808
-4,009
| -37% | -$38K |
|
|
LKFT
345
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
| $59.2K | 0.01% |
2,389
-1,380
| -37% | -$39.2K |
|
|
KALV
346
DELISTED
KalVista Pharmaceuticals
KALV
| $58.4K | 0.01% |
4,958
-3,066
| -38% | -$35.8K |
|
347
Allogene Therapeutics
ALLO
$714M
| $57.2K | 0.01% |
24,529
-7,819
| -24% | -$23.1K |
|
348
Oric Pharmaceuticals
ORIC
$1.43B
| $56K | 0.01% |
7,922
-5,000
| -39% | -$44.8K |
|
349
Ambarella
AMBA
$3.66B
| $54K | 0.01% |
1,000
| – | – |
|
350
EyePoint Inc
EYPT
$1.17B
| $53.3K | 0.01% |
6,121
-3,272
| -35% | -$45.7K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2024 Portfolio in Review
As of Q2 2024, China Universal Asset Management Company held 452 positions worth $709M, down 9.9% from $787M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
China Universal Asset Management Company withdrew a net $116M in Q2 2024, closing 40 positions and reducing 283 holdings. Its most notable exit was Super Micro Computer, an estimated $4.04M position sold in full.
By sector, the portfolio is most concentrated in Technology at 44% of assets, up from 37% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, China Universal Asset Management Company opened a new position in Arista Networks worth $5.26M.
- China Universal Asset Management Company's largest Q2 2024 buy was Arista Networks: 60,000 shares worth $5.26M.
- China Universal Asset Management Company added most to Apple in Q2 2024, an estimated $8.04M increase.
- China Universal Asset Management Company's biggest Q2 2024 reduction was Amgen, cutting an estimated $7.54M.
- China Universal Asset Management Company fully exited Super Micro Computer in Q2 2024, selling an estimated $4.04M.
- China Universal Asset Management Company's ten largest holdings make up 37% of its $709M portfolio in Q2 2024.
- China Universal Asset Management Company opened 12 new positions and closed 40 in Q2 2024.
- China Universal Asset Management Company's portfolio value fell 9.9% quarter-over-quarter to $709M.
Based on China Universal Asset Management Company's 13F filing for Q2 2024, filed 19 Jul 2024.